Menu
Search
|

Menu

Close
X

Prothena Corporation PLC PRTA.OQ (NASDAQ Stock Exchange Global Select Market)

14.77 USD
+0.39 (+2.71%)
As of 4:00 PM EDT
chart
Previous Close 14.38
Open 14.46
Volume 84,906
3m Avg Volume 293,982
Today’s High 14.79
Today’s Low 14.24
52 Week High 70.00
52 Week Low 10.44
Shares Outstanding (mil) 39.82
Market Capitalization (mil) 572.65
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.12 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
28
FY16
1
FY15
2
EPS (USD)
FY18
-1.260
FY17
-4.075
FY16
-4.656
FY15
-2.643
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.89
Price to Sales (TTM)
vs sector
20.83
8.00
Price to Book (MRQ)
vs sector
1.40
4.21
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
0.27
17.41
LT Debt to Equity (MRQ)
vs sector
0.00
13.26
Return on Investment (TTM)
vs sector
-29.84
13.14
Return on Equity (TTM)
vs sector
-36.87
15.15

EXECUTIVE LEADERSHIP

Lars Ekman
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Gene Kinney
President, Chief Executive Officer, Director, Since 2016
Salary: $520,833.00
Bonus: --
Tran Nguyen
Chief Financial Officer, Chief Operating Officer, Since 2018
Salary: $399,167.00
Bonus: --
Karin Walker
Chief Accounting Officer, Controller, Since 2016
Salary: --
Bonus: --
Wagner Zago
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Dublin 1, 25-28 North Wall Quay
DUBLIN     A96 T927

Phone: +3531.2362500

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

SPONSORED STORIES